BiotechTV - News - TopPodcast.com

Latest Episodes:

BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round Apr 02, 2025

Show notes

CEO Nicki Thompson describes why she believes the company is differentied in the field, and how TRIMTECH's construct is designed to selectively degrade aggregates that cause neurodegeneration.

Vida Ventures named Matt Cohen and Brian Goodman new Managing Directors today. BiotechTV caught up with Brian in Vida's Boston office Apr 02, 2025

Show notes

He describes his background in life sciences investing and shares his take on the current state of the sector.

After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection Apr 02, 2025

Show notes

He describes why a 'one-size-fits-all' approach has caused numerous ophthalmology trials to fail in the past, and why Character believes a precision medicine approach is overdue.

BioTrinity 2025: AlveoGene Executive Chair David Hipkiss describes the company's unique inhaled gene therapy platform that fuses a Sendai virus and Lentivirus, and can be redosed Apr 01, 2025

Show notes

He describes the science behind the platform, which is already being used by Boehringer Ingelheim for cystic fibrosis. AlveoGene has plans to use it for conditions like the surfactant protein deficiencies SP-B & ABCA3, alpha-1 antitrypsin deficiency, and IPF.

Miami based Galatea Bio raised $25M today to expand its 'Galatea Global Biobank', an initiative to sequence 10 million participants worldwide, with a focus on individuals of non-European ancestry Mar 27, 2025

Show notes

Founder and CEO Carlos Bustamante tells BiotechTV's AI Correspondent, Ryan Flinn, about the biobank and why it is important to better understand how diseases can have different profiles across diverse populations. Plus, how AI will play a role in this work.

State of Possible: Winner of the MassBioDrive Startup of the Year Award last year, the Co-Founder and CEO of Eascra Biotech describes developing nanoparticles as a delivery vehicle for therapies Mar 27, 2025

Show notes

Mari Anne Snow describes the advantages she sees nanoparticles having over current modalities like viral vectors, LNPs, and others.

State of Possible: Atlas Venture's Bruce Booth shares his take on the current state of biotech and what it takes to get through difficult times for the industry as an investor and for companies Mar 26, 2025

Show notes

He describes the 14th fund that Atlas raised at the end of last year, which was $450 million. Plus, his take on the environment, regulatory changes, China's impact on the sector, and improving biopharma's image.

State of Possible: On the one-year anniversary of the spin-out of Seaport Therapeutics, Daphne Zohar describes the Glyph platform that powers it, and her thoughts on running depression trials Mar 26, 2025

Show notes

She describes the idea of leveraging Glyph to achieve oral dosing of medicines in cases where it would not be possible or tolerable. Plus, the lead clinical program, allopregnanolone, how the company thinks about avoiding high placebo responses in trials, and other programs.

State of Possible: Beam Therapeutics' CEO John Evans discusses the company's recent alpha-1 antitrypsin deficiency data, what's ahead for sickle cell disease, and the current environment for biotech Mar 26, 2025

Show notes

He describes the nine patient dose ascending data in AAT deficiency that was historic for being the industry's first in-vivo proof of concept of a gene editor. Plus, what's next for that program and sickle cell, and the decision to do an "over the wall" financing.

State of Possible: Cigall Kadoch discusses her pioneering work in chromatin regulation that has led to Foghorn Therapeutics Mar 26, 2025

Show notes

She describes the science behind chromatin and gene regulation, previews upcoming preclinical data the company will have at AACR for its lead SMARCA2 program (partnered with Lilly), and discusses what she would like to see out of future phase 1 data.

Our TOPPODCAST Picks

Follow Us

Stay Connected

BiotechTV – News

Related Podcasts

Links

Stay Connected